Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 69,18 € (+28,92%). Mediana wynosi 71,41 € (+33,08%).
| Kupuj |
12 |
| Trzymaj |
0 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
BrightSpring Health Services expects broad growth and strong cash flow profile
At the Jefferies conference BrightSpring Health Services presented a diversified growth model focused on specialty pharmacies, home health and hospice services. Management is targeting EBITDA growth of 15–20% over the next two years and expects operating cash flow of more than US$600 million for 2026 and roughly US$500 million of free cash flow (excluding the tax impact of the Community‑Living divestiture). Leverage could fall below 2.0x by year-end, creating room for acquisitions, share buybacks or dividends. Continued growth drivers include generic drug switches, exclusive medication partnerships, technology and AI deployments, and further consolidation opportunities in the home health market. » Więcej na de.investing.com
BrightSpring accelerates growth in pharmacy and provider businesses
BrightSpring presented at the Wells Fargo Healthcare Conference a markedly accelerated EBITDA growth in the pharmacy segment (near 40% in 2025, >40% in H1 2026) and about 20% organic EBITDA growth in the provider business, supported by the integration of Amedisys LHC. Management highlighted investments in automation, AI and M&A as well as reduced leverage (near 2x EBITDA), which creates room for further acquisitions. The company expects 2026 to see the largest headwinds from IRA drug-price negotiations (around $15 million EBITDA impact), with a much smaller effect in 2027, and sees long-term tailwinds from LDD contracts, generic switches and expansion in the infusion and services business. » Więcej na de.investing.com
Secondary placement weighs on BrightSpring Health Services
Shares of BrightSpring Health Services fell about 4.4% in after-hours trading after the announcement of a secondary placement of 15 million common shares by existing shareholders, including a subsidiary of Kohlberg Kravis Roberts and members of management. BrightSpring itself is not selling any shares and will not receive proceeds from the placement. At the same time, the company approved a share buyback of up to $60 million (up to 10% of the sold shares), to be executed concurrently with the placement; Goldman Sachs is acting as sole book-running manager. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | YoY |
|---|---|---|
| Przychody | 3,39 mld | 27,08% |
| Zysk brutto | 431,75 mln | 35,76% |
| Zysk netto | 75,95 mln | 217,37% |
| EBITDA | 162,99 mln | 112,52% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 10,62 mld € |
Liczba akcji | 197,86 mln |
Maksimum/minimum z 52 tygodni | 65,83 € - 27,35 € |
| Dywidendy | Nie |
Beta | 1,88 |
C/Z (PE Ratio) | 42,03 |
PEG (PEG Ratio) | 0,13 |
C/WK (PB Ratio) | 6,05 |
C/S (PS Ratio) | 0,83 |
Profil spółki
BrightSpring Health Services, Inc. prowadzi platformę usług opieki zdrowotnej świadczonych w domu i w środowisku lokalnym w Stanach Zjednoczonych. Platforma spółki koncentruje się na świadczeniu usług farmaceutycznych i dostawców usług, w tym opieki klinicznej i wspomagającej w warunkach domowych i lokalnych, dla pacjentów objętych programami Medicare, Medicaid oraz ubezpieczonych. Obsługuje pacjentów za pośrednictwem dostawców klinicznych i farmaceutów. BrightSpring Health Services, Inc. była wcześniej znana jako Phoenix Parent Holdings Inc. i zmieniła nazwę na BrightSpring Health Services, Inc. w maju 2021 roku. Spółka została założona w 1974 roku i ma siedzibę w Louisville w stanie Kentucky.
| Nazwa | BrightSpring Health Services Inc |
| CEO | Jon Rousseau |
| Siedziba | Louisville,
ky Stany Zjednoczone |
| Strona internetowa | |
| Branża | Ochrona zdrowia: świadczeniodawcy i usługi |
| Debiut giełdowy | 26.01.2024 |
| Pracownicy | 23 500 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | BTSG |